Veracyte Q2 2026: GAAP profit, 25% EPS beat, and raised guidance
As seen on the 24/7 Wall St. homepage on July 30, 2026.
Veracyte swung to GAAP profitability while crushing EPS estimates by 25% in Q2, powered by 20% growth in Decipher Prostate and raised full-year guidance to reflect 14-15% revenue growth.
Continue ReadingShow less
Veracyte reported Q2 2026 earnings per share of $0.54, clearing the consensus estimate of $0.43 by roughly 25% and marking the company's return to GAAP profitability. Revenue came in at $150.3 million, about 4% ahead of the $144.5 million analysts had penciled in, with Decipher Prostate — the company's flagship genomic test for prostate cancer — delivering 20% growth as a key driver.
The beat extended a run of consistent outperformance: Veracyte has topped EPS estimates in each of the past eight reported quarters, with the gap between reported and estimated figures widening noticeably over the last year. The Q2 2026 EPS of $0.54 also represents the highest reported figure in that eight-quarter span, suggesting the profitability improvement is not a one-quarter anomaly.
Management followed the strong quarter by raising full-year guidance to reflect revenue growth of 14% to 15%, a signal that the company expects the Decipher Prostate momentum and broader portfolio performance to carry through the rest of 2026. Investors will be watching whether subsequent quarters can sustain the margin expansion that made GAAP profitability possible this period.
Mentioned: VCYT